Genetic variation of hepatitis C virus in a cohort of injection heroin users in Wuhan, China

Virus Research

Volumn 135, Issue 1, 2008, Pages 191-196

  Peng, Jin Song ^a,c   Wang, Xu ^d   Liu, Man Qing ^a   Zhou, Dun Jin ^a   Gong, Jie ^a   Xu, Han Ming ^b   Chen, Jian Ping ^b   Zhu, Hong Hao ^a   Zhou, Wang ^a   Ho, Wen Zhe ^d  

^a Wuhan Centers for Disease Prevention and Control   (China)

^b Wuhan Mental Health Center   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

China; Genotype; Hepatitis C virus; Injection heroin abuser; Wuhan

Indexed keywords

VIRUS ANTIBODY; VIRUS RNA;

ARTICLE; CHINA; DRUG ABUSE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; PHYLOGENY; PREVALENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; VIRUS STRAIN;

ADULT; AGE FACTORS; ANTIBODIES, VIRAL; CHINA; COHORT STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS C; HEROIN DEPENDENCE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHYLOGENY; SEX FACTORS; VARIATION (GENETICS); VIRAL PROTEINS;

HEPATITIS C VIRUS;

EID: 44549088111     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2008.01.017     Document Type: Article

References (42)

1. Alter M.J. Epidemiology of hepatitis C. Hepatology 26 3 Suppl. 1 (1997) 62S-65S
2. Alter M.J. Hepatitis C virus infection in the United States. J. Hepatol. 31 Suppl. 1 (1999) 88-91
3. Barber J.G., Crisp B.R., Ross M.W., and Wodak A. The social behavior of injecting drug users. Br. J. Soc. Work 22 (1992) 455-462
4. Berger A.M., Von D.P., Doerr H.W., Rabenau H., and Weber B. Hepatitis C plasma viral load is associated with HCV genotype but not with HIV coinfection. J. Med. Virol. 48 (1996) 339-343
5. Beyrer R.M., Lisam K., Chen J., Liu W., and Yu X.F. Overland heroin trafficking routes and HIV-1 spread in south and South-East Asia. AIDS Care 14 (2000) 75-83
6. Castro F.J., Esteban J.I., Juarez A., Sauleda S., Viladomiu L., Martell M., Moreno F., Allende H., Esteban R., and Guardia J. Early detection of nonresponse to interferon plus ribavirin combination treatment of chronic hepatitis C. J. Viral Hepatol. 9 (2002) 202-207
7. Chan C.Y., Lee S.D., Hwang S.J., Lu R.H., Lu C.L., and Lo K.J. Quantitative branched DNA assay and genotyping for hepatitis C virus RNA in Chinese patients with acute and chronic hepatitis C. J. Infect. Dis. 171 (1995) 443-446
8. Diaz T., Des Jarlais D.C., Vlahov D., Perlis T.E., Edwards V., Friedman S.R., Rockwell R., Hoover D., Williams I.T., and Monterroso E.R. Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan New York City. Am. J. Publ. Health 91 (2001) 23-30
9. Ding J., Li Y., and Tian M. Analysis of hepatitis C virus genotypes in Guizhou area, using second generation line probe assay. Zhong Hua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 13 (1999) 243-246
10. Dore G.J., Law M.G., MacDonald M., and K J.M. Epidemiology of hepatitis C virus infection in Australia. J. Clin. Virol. 26 (2003) 171-184
11. Fang Y.F., and Wang Y.M. Survey of HCV infection in intravenous drug abusers in Chongqing. Chin. J. Drug Depend. 10 (2001) 220-222
12. Forns X., and Bukh J. The molecular biology of hepatitis C virus Genotypes and quasispecies. Clin. Liver Dis. 3 (1999) 693-716
13. Jeanmougin F., Thompson J.D., Gouy M., Higgins D.G., and Gibson T.J. Multiple sequence alignment with Clustal X. Trends Biochem. Sci. Justice 23 (1998) 403-405
14. Kao J.H., Lai M.Y., Chen P.J., Hwang L.H., Chen W., and Chen D.S. Clinical significance of serum hepatitis C virus titers in patients with chronic type C hepatitis. Am. J. Gastroenterol. 91 (1996) 506-510
15. Lauer G.M., and Walker B.D. Hepatitis C virus infection. N. Engl. J. Med. 345 (2001) 41-52
16. Lee C.M., Lu S.N., Hung C.H., Tung W.C., Wang J.H., Tung H.D., Chen C.H., Hu T.H., Changchien C.S., and Chen W.J. Hepatitis C virus genotypes in southern Taiwan: prevalence and clinical implications. Trans. R. Soc. Trop. Med. Hyg. 100 (2006) 767-774
17. Liu Z., Lian Z., and Zhao C. Drug use and HIV/AIDS in China. Drug. Alcohol Rev. 25 (2006) 173-175
18. Lu L., Nakano T., He Y.S., Fu Y.S., Haqedorn C.H., and Robertson B.H. Hepatitis C virus genotype distribution in China: predominance of closely related subtype 1b isolates and existence of new genotype 6 variants. J. Med. Virol. 75 (2005) 538-549
19. Lu R.H., Hwang S.J., Chan C.Y., Chang F.Y., and Lee S.D. Quantitative measurement of serum HCV RNA in patients with chronic hepatitis C: comparison between Amplicor HCV Monitor system and branched DNA signal amplification assay. J. Clin. Lab. Anal. 12 (1998) 121-125
20. Mahaney K., Tedeschi V., Maertens G., Dibisceglie A.M., Vergalla J., Hoofnagle J.H., and Sallie R. Genotypic analysis of hepatitis C virus in American patients. Hepatology 20 (1994) 1405-1411
21. Mathei C., Buntinx F., and van Damme P. Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: a systematic review. J. Viral Hepatol. 9 (2002) 157-173
22. Matsumoto A., Tanaka E., Suzuki T., Ogata H., and Kiyosawa K. Viral and host factors that contribute to efficacy of interferon-alpha(2a) therapy in patients with chronic hepatitis C. Dig. Dis. Sci. 39 (1994) 1273-1280
23. McCoy C.B., McCoy H.Y., Lai S., Yu Z., Wang X., and Meng J. Reawakening the dragon: changing patterns of opiate use in Asia, with particular emphasis on China's Yunnan province. Subst. Use Misuse 36 (2001) 49-69
24. Orito E., Mizokami M., Nakano T., Terashima H., Nojiri O., Sakakibara H., Mizuno M., Ogino M., Nakamura M., Matsumoto Y., Miyata K.I., and L.J.Y. N. Serum hepatitis C virus RNA level as a predictor of subsequent response to interferon-alpha therapy in Japanese patients with chronic hepatitis C. J. Med. Virol. 44 (1994) 410-414
25. Pascu M., Martus P., Hohne M., Wiedenmann B., Hopf U., Schreier E., and Berg T. Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut 53 (2004) 1345-1351
26. PHYLIP F.J. Phylogenetic Inference Package. Version 3.572 (1993), Department of Genetics University of Washington, Seattle
27. Poynard T., McHutchison J., Goodman Z., Ling M.H., and Albrecht T. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?. Hepatology 31 (2000) 211-218
28. Pruett S.B., Han Y.C., and Wu W.J. A brief review of immunomodulation caused by acute administration of ethanol: involvement of neuroendocrine pathways. Alcohol Alcohol. Suppl. 2 (1994) 431-437
29. Ray S.C., Arthur R.R., Carella A., Bukh J., and Thomas D.L. Genetic epidemiology of hepatitis C virus throughout Egypt. J. Infect. Dis. 182 (2000) 698-707
30. Rebecca J., Garten S.L., Zhang J.B., Liu W., Chen J., Vlahov D., and Yu X.F. Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. Int. J. Epidemiol. 33 (2004) 182-188
31. Sherman S.G., Latkin C.A., and Gielen A.C. Social factors related to syringe sharing among injecting partners: a focus on gender. Subst. Use Misuse 36 (2001) 2113-2136
32. Stuyver L., van Arnhem W., Wyseur F., Hernandez E., Delaporte E., and Maertens G. Classification of hepatitis C viruses based on phylogenetic analysis of the envelope 1 and nonstructural 5b regions and identification of five additional subtypes. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 10134-10138
33. Teo M., and Hayes P. Management of hepatitis C. Br. Med. Bull. 70 (2004) 51-69
34. Thomas D.L., Cannon R.O., Shapiro C.N., Hook III E.W., Alter M.J., and Quinn T.C. Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. J. Infect. Dis. 169 (1994) 990-995
35. Thomas D.L., Vlahov D., Solomon L., Cohn S., Taylor E., Garfein R., and Nelson K.E. Correlates of hepatitis C virus infections among injection drug users. Medicine 74 4 (1995) 212-220
36. Verachai V., Phutiprawan T., Theamboonlers A., Chinchai T., Tanprasert S., Haagmans B.L., Osterhaus A.D., and P Y. Prevalence and genotypes of hepatitis C virus infection among drug addicts and blood donors in Thailand Southeast Asian. J. Trop. Med. Publ. Health 33 (2002) 849-851
37. Wyld R., Robertson J.R., Brettle R.P., Mellor J., Prescott L., and Simmonds P. Absence of hepatitis C virus transmission but frequent transmission of HIV-1 from sexual contact with doubly-infected individuals. J. Infect. 35 (1997) 163-166
38. Yamada G., Takatani R., Kishi F., Takahashi M., Doi T., Tsuji T., Shin S., Tanno M., Urdea M.S., and K.J. A. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 22 (1995) 1351-1354
39. Yang J.H., Lai J.P., Douglas S.D., Metzger D., Zhu X.H., and Ho W.Z. Real-time RT-PCR for quantitation of hepatitis C virus RNA. J. Virol. Methods 102 (2002) 119-128
40. Yu M.L., Chuang W.L., Chen S.C., Lin Z.Y., Hsieh M.Y., Wang L.Y., and Chang W.Y. Clinical application of the Quantiplex HCV RNA 2, 0 and Amplicor HCV Monitor assays for quantifying serum hepatitis C virus RNA. J. Clin. Pathol. 52 (1999) 807-811
41. Zhang C.Y., Yang R., Xia X.S., Qin S.Y., Dai J.P., Zhang Z.B., Peng Z.Z., Wei T., Liu H., Pu D.C., Luo J.H., Takebe Y.T.K., and Ben K.L. High prevalence of HIV-1 and hepatitis C virus coinfection among injection drug users in the southeastern region of Yunnan, China. J. Acquir. Immune Defic. Syndr. 29 (2002) 191-196
42. Zhao C.Z., Liu Z.M., Zhao D., Liu Y.H., Liang J.H., Tang Y.L., Liu Z.Y., and Zheng J.W. Drug abuse in China. Ann. N.K. Acad. Sci. 1025 (2004) 439-445